Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in this application.

1. (currently amended) A chimeric, humanized or human antibody that competitively inhibits binding of an amphiregulin polypeptide to an anti-amphiregulin antibody, wherein the amphiregulin polypeptide ~~comprises~~ consists essentially of SEQ ID NO: 1, and wherein the anti-amphiregulin antibody comprises a heavy chain variable region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4 and 12 and a light chain variable region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 5 and 14 ~~and the anti-amphiregulin antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:2, 3, 4, 5, 12, and 14~~.

2. (cancelled)

3. (previously presented) The antibody of claim 1, wherein the anti-amphiregulin antibody is selected from the group consisting of: an antibody comprising SEQ ID NO: 2 and SEQ ID NO: 3; an antibody comprising SEQ ID NO: 4 and SEQ ID NO: 5; and an antibody comprising SEQ ID NO: 12 and SEQ ID NO: 14.

4. (previously presented) The antibody of claim 1, wherein the antibody comprises SEQ ID NO: 12 and SEQ ID NO: 14.

5. (original) The antibody of claim 1, wherein the antibody is an antibody fragment.

6. (original) The antibody of claim 5, wherein the antibody fragment is selected from the group consisting of Fab, Fab', $F(ab')_2$, Fv fragments, rIgG, diabodies, single chain antibodies, and multispecific antibodies.

7. (original) The antibody of claim 1, wherein the antibody is conjugated to an effector moiety.

8. (previously presented) The antibody of claim 1, wherein the amphiregulin polypeptide is on a cancer cell.

9. (previously presented) The antibody of claim 1, wherein the amphiregulin polypeptide is on a skin cell.

10. (currently amended) A chimeric, humanized or human antibody comprising a heavy chain variable region having an amino acid sequence of at least 95% identity to a sequence selected from the group consisting of SEQ ID NOs: 2, 4 and 12, and a light chain variable region having an amino acid sequence of at least 95% identity to a sequence selected from the group consisting of SEQ ID NOs: 3, 5 and 14.

11. (cancelled)

12. (cancelled)

13. (original) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the antibody of claim 1.

14. (original) The pharmaceutical composition of claim 13, wherein the antibody is conjugated to an effector moiety.

15. (original) The pharmaceutical composition of claim 13, wherein the antibody comprises SEQ ID NO: 12 and SEQ ID NO: 14.

16. (cancelled)

17. (cancelled)

18. (currently amended) A chimeric, humanized or human antibody that specifically binds to ~~a~~ an amphiregulin polypeptide, wherein the amphiregulin polypeptide ~~comprises~~ consists essentially of SEQ ID NO: 1, and wherein the antibody binds to the same amphiregulin epitope as that bound by an antibody selected from the group consisting of: an antibody comprising a heavy chain variable region of SEQ ID NO: 2 and a light chain variable region of SEQ ID NO: 3; an antibody comprising a heavy chain variable region of SEQ ID NO: 4 and a light chain variable region of SEQ ID NO: 5; and an antibody comprising a heavy chain variable region of SEQ ID NO: 12 and a light chain variable region of SEQ ID NO: 14.

19. (cancelled)

20. (previously presented) The antibody of claim 18, wherein the antibody is an antibody fragment selected from the group consisting of Fab, Fab', $F(ab')_2$, Fv fragments, rIgG, diabodies, single chain antibodies and multispecific antibodies.

21. (previously presented) The antibody of claim 18, wherein the antibody inhibits proliferation of tumor cells.

22. (previously presented) The antibody of claim 18, wherein the antibody inhibits *in vivo* proliferation of tumor cells that express amphiregulin.

23. (previously presented) The antibody of claim 18, wherein the antibody neutralizes at least one biological activity of amphiregulin.

24. (previously presented) The antibody of claim 18, wherein the antibody is conjugated to an effector moiety.

25. (previously presented) The antibody of claim 18, wherein the antibody competes for binding to the ligand binding site of a ligand of amphiregulin.

26. (cancelled)

27. (cancelled)

28. (previously presented) A hybridoma producing the antibody of claim 18.

29. (cancelled)

30. (cancelled)

31. (cancelled)

32. (currently amended) A polypeptide comprising ~~a~~ an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 3, 4, 5, 12 and 14.

33. (cancelled)

34. (cancelled)

35. (cancelled)

36. (cancelled)

37. (cancelled)

38. (cancelled)

39. (cancelled)

40. (cancelled)

41. (cancelled)

42. (cancelled)

43. (cancelled)

44. (cancelled)

45. (cancelled)

46. (new) A chimeric, humanized or human antibody that specifically binds to a polypeptide consisting of SEQ ID NO: 1.

47. (new) The antibody of claim 46, wherein the antibody comprises a heavy chain variable region of SEQ ID NO: 2 and a light chain variable region of SEQ ID NO: 3.

48. (new) The antibody of claim 46, wherein the antibody comprises a heavy chain variable region of SEQ ID NO: 4 and a light chain variable region of SEQ ID NO: 5.

49. (new) The antibody of claim 46, wherein the antibody comprises a heavy chain variable region of SEQ ID NO: 12 and a light chain variable region of SEQ ID NO: 14.